Medication info
Sitaren Duo Tablets 50/1000 mg (Sitagliptin, Metformin Hydrochloride)

Sitaren Duo Tablets 50/1000 mg (Sitagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200031 · Approved 2022.01.03 · Insurance code 662504700

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom this medicine should not be used). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this medicine should not be used).

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise therapy to assist patients with type 2 diabetes in controlling their blood sugar levels. It may be used for those who are newly receiving diabetes medication or have difficulty controlling blood sugar with other monotherapies. Additionally, this medication can be beneficial when metformin or sitagliptin alone is insufficient, or when replacing a treatment that involved combining these two medications. If adequate blood sugar control is not achieved with a combination of metformin and sulfonylureas, thiazolidinediones, or insulin, this medication can be used to improve blood sugar control. Therefore, this medication serves as an effective adjunct therapy for patients who struggle to control their blood sugar despite multiple medication regimens. This medication improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom this medicine should not be used). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this medicine should not be used).

Precautions

This medication is used for diabetes treatment and contains two active ingredients, sitagliptin and metformin. During treatment with this medication, allergic reactions may occur; therefore, if symptoms such as skin rash or difficulty breathing arise, discontinue use immediately and consult a physician. There may be a risk of acute pancreatitis, so if symptoms such as abdominal pain, nausea, or vomiting occur, monitor closely and inform your doctor. This medication should not be used in patients with impaired kidney function, acute heart issues, or those who are pregnant or breastfeeding. Particularly, patients with reduced kidney function should have thorough discussions with their physician before taking this medication and should undergo regular kidney function tests. Moreover, during acute infections, dehydration, or before and after significant trauma or surgery, it may be necessary to temporarily discontinue this medication. When taking this medication, if meal amounts are irregular or if engaging in strenuous exercise, there is a risk of side effects such as hypoglycemia or lactic acidosis; caution is advised. Side effects such as diarrhea, nausea, headache, and upper respiratory infections may occur, and immediate treatment is required in cases of severe hypoglycemia. Additionally, this medication may have interactions if taken with other hypoglycemic agents or certain medications, so inform your doctor of all medications being taken. Alcohol consumption may increase the risk of lactic acidosis; therefore, it is advisable to avoid drinking during treatment. If undergoing surgery or contrast studies using iodine, the use of this medication should be suspended for a certain period, and it should only be resumed after confirming that kidney function is normal. Elderly individuals may have a higher risk of diminished kidney function, so kidney function should be monitored more carefully during treatment with this medication. Pregnant women or those who might become pregnant and breastfeeding mothers should not use this medication. If an overdose occurs, seek medical attention immediately, as this medication can be partially removed by dialysis. Finally, if any abnormal symptoms develop during treatment with this medication, consult a doctor immediately and continue treatment with regular monitoring of blood sugar and kidney function.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • constipation
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air from entering, at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.